Antisense Therapeutics Limited
October 17, 2023
Company Description: Antisense Therapeutics Limited (ASX: ANP; OTC: ATHJY) is an Australian biotechnology company focused on rare diseases. Through a partnership with Ionis Pharmaceuticals (NASDAQ: IONS), the company has developed a pipeline of novel antisense oligonucleotide therapies. The company's lead asset is ATL1102, an antisense oligonucleotide therapy in development for Duchenne muscular dystrophy. Following positive phase IIa data, the company has recently launched an international phase IIb randomized controlled trial, which is expected to read out in 2H CY2024. The company's second asset is ATL1103, which is in phase II for acromegaly.
CEO/Top Company Official
Dr James Garner - Chief Executive Officer and Managing Director
Lead Product in Development
Development Phase of Primary Product
Number Of Unlicensed Products